Skip to main content
Erschienen in: International Journal of Hematology 4/2014

01.04.2014 | Original Article

Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients

verfasst von: Akihiro Shindo, Hideo Wada, Hidehiro Ishikawa, Ai Ito, Masaru Asahi, Yuichiro Ii, Makoto Ikejiri, Hidekazu Tomimoto

Erschienen in: International Journal of Hematology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The clinical symptoms, causative factors, and prognosis in Japanese patients with cerebral venous thrombosis have not been adequately characterized. The present study describes these features in patients in Japan. Twenty-two patients with cerebral venous thrombosis were retrospectively identified. Diagnosis was confirmed by either digital subtraction angiography, magnetic resonance venography, or contrast-enhanced computed tomography. Demographic data and clinical and radiological features were recorded and analyzed for each patient. Prognosis was evaluated by the modified Rankin scale (mRS) at the time of hospital discharge. The most frequent symptom of cerebral venous thrombosis was headache (59.1 %). Causative factors included congenital thrombophilia (31.8 %), acquired thrombophilia (27.3 %), and iron-deficiency anemia (13.6 %). Of seven patients with congenital thrombophilia, four had mutations in the protein S gene, two had mutations in the protein C gene, and one had mutations in the antithrombin gene. All patients were alive at discharge from hospital. Nineteen of the 22 patients (86.4 %) recovered completely or exhibited only mild residual symptoms (mRS 0–2). However, three patients (13.6 %) had a poor prognosis (mRS 3–5). Cerebral venous thrombosis in Japanese patients is frequently associated with congenital thrombophilia and protein S gene mutation.
Literatur
1.
Zurück zum Zitat Guenther G, Arauz A. Cerebral venous thrombosis: a diagnostic and treatment update. Neurologia. 2011;26:488–98.PubMedCrossRef Guenther G, Arauz A. Cerebral venous thrombosis: a diagnostic and treatment update. Neurologia. 2011;26:488–98.PubMedCrossRef
2.
3.
Zurück zum Zitat Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992;10:87–111.PubMed Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992;10:87–111.PubMed
4.
Zurück zum Zitat Ogata T, Kamouchi M, Kitazono T, Kuroda J, Ooboshi H, Shono T, et al. Cerebral venous thrombosis associated with iron deficiency anemia. J Stroke Cerebrovasc Dis. 2008;17:426–8.PubMedCrossRef Ogata T, Kamouchi M, Kitazono T, Kuroda J, Ooboshi H, Shono T, et al. Cerebral venous thrombosis associated with iron deficiency anemia. J Stroke Cerebrovasc Dis. 2008;17:426–8.PubMedCrossRef
5.
Zurück zum Zitat Shindo A, Ikejiri M, Ii Y, Nakatani K, Wada H, Nobori T, et al. A novel protein S gene mutation combined with protein S Tokushima mutation in a patient with superior sagittal sinus thrombosis. J Neurol. 2012;259:178–9.PubMedCrossRef Shindo A, Ikejiri M, Ii Y, Nakatani K, Wada H, Nobori T, et al. A novel protein S gene mutation combined with protein S Tokushima mutation in a patient with superior sagittal sinus thrombosis. J Neurol. 2012;259:178–9.PubMedCrossRef
6.
Zurück zum Zitat Ikejiri M, Shindo A, Ii Y, Tomimoto H, Yamada N, Matsumoto T, et al. Frequent association of thrombophilia in cerebral venous sinus thrombosis. Int J Hematol. 2012;95:257–62.PubMedCrossRef Ikejiri M, Shindo A, Ii Y, Tomimoto H, Yamada N, Matsumoto T, et al. Frequent association of thrombophilia in cerebral venous sinus thrombosis. Int J Hematol. 2012;95:257–62.PubMedCrossRef
7.
Zurück zum Zitat Yoshikawa T, Abe O, Tsuchiya K, Okubo T, Tobe K, Masumoto T, et al. Diffusion-weighted magnetic resonance imaging of dural sinus thrombosis. Neuroradiology. 2002;44:481–8.PubMedCrossRef Yoshikawa T, Abe O, Tsuchiya K, Okubo T, Tobe K, Masumoto T, et al. Diffusion-weighted magnetic resonance imaging of dural sinus thrombosis. Neuroradiology. 2002;44:481–8.PubMedCrossRef
8.
Zurück zum Zitat Van Swieten JC, Koudstall PJ, Visser MC, Shouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1989;19:604–7.CrossRef Van Swieten JC, Koudstall PJ, Visser MC, Shouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1989;19:604–7.CrossRef
9.
Zurück zum Zitat Ikejiri M, Tsuji A, Wada H, Sakamoto Y, Nishioka J, Ota S, et al. Analysis three abnormal protein S genes in a patient with pulmonary embolism. Thromb Res. 2010;125:529–32.PubMedCrossRef Ikejiri M, Tsuji A, Wada H, Sakamoto Y, Nishioka J, Ota S, et al. Analysis three abnormal protein S genes in a patient with pulmonary embolism. Thromb Res. 2010;125:529–32.PubMedCrossRef
10.
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.PubMedCrossRef Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.PubMedCrossRef
11.
Zurück zum Zitat Teasdale G, Jannett B. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974;2:81.PubMedCrossRef Teasdale G, Jannett B. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974;2:81.PubMedCrossRef
12.
Zurück zum Zitat Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, for the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664–70.PubMedCrossRef Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, for the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664–70.PubMedCrossRef
13.
Zurück zum Zitat Canhão P, Ferro JM, Lindgren AG, Bousser MG, Stam J, Barinagarrementaria F, for the ISCVT Investigators. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36:1720–5.PubMedCrossRef Canhão P, Ferro JM, Lindgren AG, Bousser MG, Stam J, Barinagarrementaria F, for the ISCVT Investigators. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36:1720–5.PubMedCrossRef
14.
Zurück zum Zitat Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F, for the ISCVT Investigators. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005;36:1927–32.PubMedCrossRef Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F, for the ISCVT Investigators. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005;36:1927–32.PubMedCrossRef
15.
Zurück zum Zitat Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J, for the Cerebral Venous Thrombosis Portuguese Collaborative Study Group. Long-term prognosis of cerebral vein and dural sinus thrombosis: results of the VENOPORT study. Cerebrovasc Dis. 2002;13:272–8.PubMedCrossRef Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J, for the Cerebral Venous Thrombosis Portuguese Collaborative Study Group. Long-term prognosis of cerebral vein and dural sinus thrombosis: results of the VENOPORT study. Cerebrovasc Dis. 2002;13:272–8.PubMedCrossRef
16.
17.
Zurück zum Zitat Simchen MJ, Goldstein G, Lubetsky A, Strauss T, Schiff E, Kenet G. Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke. 2009;40:65–70.PubMedCrossRef Simchen MJ, Goldstein G, Lubetsky A, Strauss T, Schiff E, Kenet G. Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke. 2009;40:65–70.PubMedCrossRef
18.
Zurück zum Zitat Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55:850–5.PubMedCrossRef Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55:850–5.PubMedCrossRef
19.
Zurück zum Zitat Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002;126:1326–36.PubMed Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002;126:1326–36.PubMed
20.
Zurück zum Zitat Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res. 1995;77:1–43.PubMedCrossRef Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res. 1995;77:1–43.PubMedCrossRef
21.
Zurück zum Zitat Beauchamp NJ, Dykes AC, Parikh N, Campbell Tait R, Daly ME. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol. 2004;125:647–54.PubMedCrossRef Beauchamp NJ, Dykes AC, Parikh N, Campbell Tait R, Daly ME. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol. 2004;125:647–54.PubMedCrossRef
23.
Zurück zum Zitat Segers K, Dhalbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007;98:530–42.PubMed Segers K, Dhalbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007;98:530–42.PubMed
24.
Zurück zum Zitat Vicente V, González-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica. 1999;84:356–62.PubMed Vicente V, González-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica. 1999;84:356–62.PubMed
25.
Zurück zum Zitat Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70:126–32.PubMedCrossRef Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70:126–32.PubMedCrossRef
26.
Zurück zum Zitat Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost. 1995;74:996.PubMed Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost. 1995;74:996.PubMed
27.
Zurück zum Zitat Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol. 2006;83:217–23.PubMedCrossRef Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol. 2006;83:217–23.PubMedCrossRef
28.
Zurück zum Zitat Kimura K, Honda S, Kawasaki T, Tsuji H, Madoiwa S, Sakata Y, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006;107:1737–8.PubMedCrossRef Kimura K, Honda S, Kawasaki T, Tsuji H, Madoiwa S, Sakata Y, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006;107:1737–8.PubMedCrossRef
29.
Zurück zum Zitat Neki R, Fujita T, Kokame K, Nakanishi I, Waguri M, Imayoshi Y, et al. Genetic analysis of patients with deep vein thrombosis during pregnancy and postpartum. Int J Hematol. 2011;94:150–5.PubMedCrossRef Neki R, Fujita T, Kokame K, Nakanishi I, Waguri M, Imayoshi Y, et al. Genetic analysis of patients with deep vein thrombosis during pregnancy and postpartum. Int J Hematol. 2011;94:150–5.PubMedCrossRef
30.
Zurück zum Zitat Sato R, Iwasawa M. Contraceptive use and induced abortion in Japan: how is it so unique among the developed countries? Jpn J Popul. 2006;4:33–54. Sato R, Iwasawa M. Contraceptive use and induced abortion in Japan: how is it so unique among the developed countries? Jpn J Popul. 2006;4:33–54.
31.
Zurück zum Zitat Khealani BA, Wasay M, Saadah M, Sultana E, Mustafa S, Khan FS, et al. Cerebral venous thrombosis: a descriptive multicenter study of patients in Pakistan and Middle East. Stroke. 2008;39:2707–11.PubMedCrossRef Khealani BA, Wasay M, Saadah M, Sultana E, Mustafa S, Khan FS, et al. Cerebral venous thrombosis: a descriptive multicenter study of patients in Pakistan and Middle East. Stroke. 2008;39:2707–11.PubMedCrossRef
Metadaten
Titel
Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients
verfasst von
Akihiro Shindo
Hideo Wada
Hidehiro Ishikawa
Ai Ito
Masaru Asahi
Yuichiro Ii
Makoto Ikejiri
Hidekazu Tomimoto
Publikationsdatum
01.04.2014
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2014
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1550-x

Weitere Artikel der Ausgabe 4/2014

International Journal of Hematology 4/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.